Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes
Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes
This trial is conducted in Europe. The aim of this trial is to compare different ratios of
 explorative formulations, not similar to the proposed commercial formulation, of IDegAsp
 (co-formulation of insulin degludec/insulin aspart and insulin aspart) with separately
 injected, simultaneous doses of insulin degludec (insulin 454), and insulin aspart, compared
 with biphasic insulin aspart 30 in male subjects with type 1 and type 2 diabetes mellitus.

 Trial part 1 is a five-period cross-over trial with incomplete block-design in subjects with
 type 1 diabetes where each subject will be randomised to five out of the ten possible
 treatments. Each treatment consists of an injection of the insulin product followed by a
 euglycemic clamp with a washout period of 7-15 days between treatments.

 Trial part 2 is a three-period cross-over trial with complete blockdesign in subjects with
 type 2 diabetes. Each treatment consists of an injection of the insulin product followed by a
 euglycaemic clamp with a washout period of 7-15 days between treatments.
Inclusion Criteria:

 -  The subject will be a male volunteer, who is considered to be generally healthy,
 except for underlying diabetes mellitus and concomitant medical complications (e.g.
 hypertension) based on an assessment of medical history, physical examination and
 clinical laboratory data, as judged by the Investigator

 -  Glycosylated haemoglobin A1c (HbA1c) below or equal to 10 % based on central
 laboratory results

 -  ADDITIONAL INCLUSION CRITERA FOR SUBJECTS WITH TYPE 1 DIABETES:

 -  Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12
 months

 -  Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive)

 -  ADDITIONAL INCLUSION CRITERA FOR SUBJECTS WITH TYPE 2 DIABETES:

 -  Diagnosed with type 2 diabetes mellitus for at least 12 months

 -  Treated with insulin for the last 3 months prior to screening.

 -  Body Mass Index (BMI) between 22.0 and 35.0 kg/m^2 (both inclusive)

 Exclusion Criteria:

 -  A subject with a history of significant multiple drug allergies or with a known or
 suspected allergy to the trial product or any medicine chemically related to the trial
 product, as judged by the Investigator

 -  A subject who has participated in any other trials involving investigational products
 within the 3 months preceding the start of dosing